Company description

MedPharm Ltd. is a leading, global provider of contract topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through the use of proprietary, industry-leading performance testing models. Well-established as a global leader in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm also offers innovative solutions for ophthalmic and airway preparations. These solutions are recognized for their scientific rigor by regulators and investors. MedPharm has fully established R&D centres in the US and U.K. and GMP clinical manufacturing at its global headquarters facility in Guildford, UK. For more information visit our website http://www.medpharm.com.

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Central/South America
Affiliated categories: Aerosols |Analytical Chemistry |Analytical Development More

Upcoming events

9 sep 2020

CPhI North America 2020

9 - 11 Sep 2020 Philadelphia, USA Visit us at stand 951 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

30 apr 2019

CPhI North America 2019

30 April - 2 May 2019 Chicago, USA We were at stand 2344 See our Exhibitor Profile   See full Exhibitor List

News about MedPharm, Ltd

Positive update on the development of new XF‐platform drug formulations

24 Mar 2020

Positive update on the development of new XF‐platform drug formulations

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Read more

5 Dec 2019

MedPharm moves into $4M expansion of its North Carolina facility

Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.

Read more

19 Feb 2019

Partnership expands to develop a new treatment for pachyonychia congenita

MedPharm and Palvella Therapeutics hope to develop the first approved treatment for PC in the US and Europe.

Read more

14 Jan 2019

MedPharm expands to de-risk customers' development programs

The $4-million investment will be used to expand topical dosage formulation development services and innovative performance testing on topical and transdermal pharmaceutical products.

Read more
MedPharm, Ltd

Contact information




View all contact information